Philippines Mulls Qdenga Dengue Vaccine: Learning from Dengvaxia
The Department of Health is evaluating the Qdenga vaccine for dengue prevention, mindful of past experiences.
Qdenga Vaccine Under Review
Health Secretary Teodoro Herbosa stated the government is actively evaluating the potential introduction of the Qdenga vaccine in the Philippines to protect children from dengue fever.
Dengvaxia Lessons Learned
The decision-making process is heavily influenced by the lessons learned from the Dengvaxia controversy. A thorough and cautious approach is being taken to ensure public safety and confidence in the vaccine.
FDA Review Process
The Food and Drug Administration (FDA) is currently reviewing the application submitted by Japan-based Takeda Pharmaceutical Co. for the Qdenga vaccine. The review process includes a careful assessment of its efficacy and safety profile.
Potential Benefits of Qdenga
Qdenga has shown promising results in clinical trials, offering broader protection against different dengue serotypes compared to previous vaccines. Learn more about Dengue Fever.
Next Steps for the Philippines
The government will continue to monitor the FDA's review and conduct further consultations with experts before making a final decision on whether to include Qdenga in the national immunization program. Further information will be available on the Department of Health Website.
